Publications 2024

[nb:]Ranji P, Jonasson E, Andersson L, Filges S, Santamaría ML, Vannas C, Dolatabadi S, Gustafsson A, Myklebost O, Håkansson J, Fagman H, Landberg G, Åman P, Ståhlberg A (2024) Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development. J Transl Med 10.1186/s12967-024-05211-w

Sveen A, Johannessen B, Klokkerud SM, Kraggerud SM, Meza-Zepeda LA, Bjørnslett M, Bischof K, Myklebost O, Taskén K, Skotheim RI, Dørum A, Davidson B, Lothe RA (2024). Evolutionary mode and timing of dissemination of high-grade serous carcinomas. JCI Insight. e170423. doi: 10.1172/jci.insight.170423

Zhou Y, Ray PS, Zhu J, Stein F, Rettel M, Sekaran T, Sahadevan S, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA, von Deimling A, Fu C, Brosig AN, Boye K, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2024) Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma Nat Commun DOI: 10.1038/s41467-024-47031-y

Publications 2023

Anzar, I., B. Malone, P. Samarakoon, I. Vardaxis, B. Simovski, H. Fontenelle, L. A. Meza-Zepeda, R. Stratford, E. Keung, M. Burgess, H. A. Tawbi, O. Myklebost and T. Clancy (2023). «The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition.» Front. Immunol. doi: 10.3389/fimmu.2023.1226445

Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O, Meza-Zepeda LA, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour JV, Li S, Nguyen TL, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Ahn JH, Kim JU, Randall RL, Tucker K, Judson I, Sarin R, Haber M, Marshall G, Cairns MJ, Blay JY, Thomas DM (2023) Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science doi: 10.1126/science.abj4784

Namløs HM, Khelik K, Nakken S, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2023) Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential. Molecular Oncology doi:10.1002/1878-0261.13514 

Pioneer postdoc announcement


Postdoctoral Research Fellow in pediatric cancer biology

UiB – Knowledge that shapes society

Through robust and close interaction with the world around us – globally, nationally and locally – we shall be instrumental in building a society based on knowledge, skills and attitudes.

Do you want to take part in shaping the future?

Postdoctoral Research Fellow position

Funded by a highly competitive Pioneer Grant for novel and game-changing projects.

At the Faculty of Medicine, Department of Clinical Science, a full-time (100 %) position as Postdoctoral Research Fellow is available for a period of two (2) years. The position is part of the project, ”KidImmune – Autoimmune mechanisms in pediatric cancer”, financed by the Norwegian Cancer Society Pioneer Program. See for more information.

Our small, enthusiastic group consisting of Ola Myklebost, an experienced cell biologist and cancer researcher, and research fellow Anastassia Serguienko, who made the entirely novel discoveries on which this project is built, has the focus completely on this project. Our findings open up a Pandora’s box of fascinating questions that need answers. We have laid a solid foundation of clinical sample collections, proteomic data, technologies, and cell models to give the candidate a flying start.

We have access to expert in-house core facilities for genomics, proteomics, flow cytometry and advanced microscopy.

About the project/work tasks:

  • Investigations on how patient autoantibodies may influence important processes in normal and cancer cells in culture
  • Using immunohistochemistry, advanced microscopy, flow cytometry, protein chemistry, and various functional assays

Qualifications and personal qualities:

  • The applicant must hold a Norwegian PhD or an equivalent degree or have submitted the doctoral thesis prior to the application deadline. It is a condition of employment that the PhD has been awarded at the latest within 31.12.2022
  • Work independently and in a structured manner and have good ability to communicate and cooperate.
  • Proficiency in both written and oral English is required. Proficiency in Norwegian would be an advantage
  • Special requirements for the position: Project experience from mammalian molecular and cell biology is required, including cellular structure and function or advanced human immunology. Competence in excess of course experience in immunology, protein chemistry and function, advanced cell microscopy, or cancer biology would be an advantage

About the position of postdoctoral research fellow:

The position of postdoctoral research fellow is a fixed-term appointment with the primary objective of qualifying the appointee for work in top academic positions. Postdoctoral fellowships are fixed term positions. You can not be employed as a postdoctoral fellow for more than one three-year period at the same institution.

We can offer:

Your application must include:

  • A brief account of the applicant`s research interests and motivation for applying for the position
  • Transcripts and diplomas (applicants with education from other countries than Norway must enclose witnessed diplomas in both the original language and authorized translations) and documentation of submitted doctoral thesis
  • Complete list of publications
  • Publications (pdf) it is important that each of the scholarly works on which the committee should place special emphasis, is attached in its entirety
  • Two referees (name and contact information)

General information:

For further information please contact prof. Ola Myklebost, e-mail: phone: +47 55974573 / +47 90087139

The state labour force shall reflect the diversity of Norwegian society to the greatest extent possible. People with immigrant backgrounds and people with disabilities are encouraged to apply for the position.

The University of Bergen applies the principle of public access to information when recruiting staff for academic positions.

Information about applicants may be made public even if the applicant has asked not to be named on the list of persons who have applied. The applicant must be notified if the request to be omitted is not met.

Further information about our employment process can be found here.

Publications 2022

Namløs H, Skårn M, Ahmed D, Grad I, Andresen K, Kresse S, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O, Lind G, Meza-Zepeda LA (2022) miR-486 expression is regulated by DNA methylation in osteosarcoma BMC Genomics 23:142. doi: 10.1186/s12864-022-08346-6

Misund K, Hofste op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA, Sundan A, Myklebost O, Sonneveld P, Waage A. (2022) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence Leukemia 10.1038/s41375-022-01597-y 

Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022) Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel  monotherapy Genome Med DOI: doi: 10.1186/s13073-022-01090-2 

Publications 2021

Georgiesh T, Namløs HM, Sharma N, Lorenz S, Myklebost O, Bjerkehagen B, Meza-Zepeda LA, Boye K (2021) Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumor. Pathology 53:713-719 doi:10.1016/j.pathol.2020.11.010

Grad I, Hanes R, Ayuda-Durán P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O (2021) Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening. PLoS DOI:10.1371/journal.pone.0248140 

Nakken S, Saveliev V, Hofmann O, Møller P, Myklebost O, Hovig E (2020) Cancer Predisposition Sequencing Reporter (CPSR): a flexible variant report engine for high-throughput germline screening in cancer.  Int J Cancer Vol.149(11), p.1955-1960 doi: 10.1002/ijc.33749 

Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chi-card M, Sheffield NC, Pierron G, Lapouble E, Tötzl M, Ergüner B, Barre-ca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost O, Marec-Berard P, Burchill SA, Brennan B, Strauss SJ, Whelan J, Schleiermacher G, Dirksen U, Hutter C, Boye K, Ambros PF, Delattre O, Metzler M, Bock C, Tomazou E (2021) Accurate detection and classification of Ewing sarcoma tumors based on cell-free DNA fragmentation patterns inferred from whole genome sequencing. Nature Communications 28;12(1):3230. doi: 10.1038/s41467-021-23445-w

Stabell M, Sæther T, Røhr ÅK, Gabrielsen OS, Myklebost O (2021) Methylation-dependent SUMOylation of the architectural transcription factor HMGA2. Biochemical and Biophysical Research Communications, doi: 10.1016/j.bbrc.2021.02.099 

Sveen A, Johannessen B, Eilertsen IA, Røsok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O, Bjørnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021) The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine 13:142. doi: 10.1186/s13073-021-00955-2  

Informasjon for pasienter

I alle våre prosjekter bruker vi prøver fra og opplysninger om pasienter for å forstå disse komplekse sykdommene bedre og identifisere sider ved dem som kan utnyttes for bedre diagnostikk, behandling eller oppfølgning.

I to nye prosjekter studerer vi arvelige risikovarianter som kan gi stor risiko for sarkom, og, på bakgrunn av en intervjuundersøkelse med pasienter i NoSarC-prosjektet, arbeider vi med prosedyrer som kan velge ut hvilke av disse variantene som vi vet nok om til å melde tilbake til pasienten, og hvordan dette bør gjøres.

I et annet prosjekt studerer vi om pasientene i NoSarC har antistoff rette mot kreftcellene, og om disse kan utnyttes i nye former for immunterapi.

Trykk på ⋁-tegnet i venstremenyen for å lese om de andre prosjektene.

Informasjon om osteosarkomstudien i det internasjonale kreftgenomprosjektet (ICGC)

I 2011 ble vi med på en internasjonal studie av arvestoffets struktur i prøver fra noen av Radiumhospitalets pasienter med osteosarkom (ondartede bensvulster). Dette var en forlengelse av vårt samarbeid i det europeiske «Network of Excellence on Bone Tumours», der vi var av de få som hadde en høykvalitetssamling av prøver fra slike pasienter, som var samlet over flere år av ortopedene. I dette prosjektet skulle hele arvestoffet (DNAet, to ganger 3 milliarder byggesteiner) analysert i både blod og svulst og sammenlignet for hver pasient. Vi innhentet derfor samtykke fra de aktuelle pasientene, og ba også om en blodprøve fra hver.

Dette er svært kostbare analyser, og mange av svulstprøvene hadde ikke høy nok kvalitet, det kunne være lite kreftvev i dem, eller arvestoffet kunne være ødelagt pga innsamlings- eller lagringsprosdyerene, men vi fikk med 27 slike par med svulst- og blodprøver. Resultatene har bidratt til flere meget høyprofilert vitenskapelige artikler, og både data og prøver er ennå til stor nytte i nye prosjekter.

Dette var den opprinnelige artiklen der resultatene fra våre pasienter ble presentert:

Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O, Bjerkehagen B, Myklebost O, Amary MF, Tirabosco R, Van Loo P, Stratton MR, Flanagan AM, Campbell PJ (2017) Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma Nature Communications 23:15936 doi: 10.1038/ncomms15936 

Resultatene har videre bidratt i disse store samarbeidsartiklene:

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium [Incl Bjerkehagen B, Myklebost O, Zaikova O] (2020) Pan-cancer analysis of whole genomes. Nature 578:82–93 doi:10.1038/s41586-020-1969-6 

Ju YS, Tubio JMC, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A,Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Ta M, Lee M, van’t Veer LJ, Tan BKT, Aparicio S, Span PN, Martens JWM, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PM, Stratton MR (2015) Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research 25:814-24. doi: 10.1101/gr.190470.115. 

Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O’Meara S, Andreson E, Maddison M, Gamble S, ICGC Breast Cancer Group, ICGC Bone Cancer Group, ICGC Prostate Cancer Group, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van’t Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio A, Foekens JA, Eyfjörd JE, Lakhani SR, Thomas G, Myklebost O, Span PN, Børresen-Dale AL, Richardson AL,van de Vijver M, Vincent-Salomon A, van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ (2014Extensive transduction of non-repetitive DNA mediated by L1 retrotransposition in cancer genomes.  Science 345 no. 6196 DOI: 10.1126/science.1251343 

Behjati S, Tarpey PS, Presneau N, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gudem G, Davies H, Nik-Zainal S, Gamble J, Hardy C, Latimer C, Maddison M, Martin S, McLaren S, Mudie L, O’Meara S, Robinson B, Butler A, Teague JW, Kathri B, Halai D, Myklebost O, Baumhoer D, Jundt G, Tirabosco R, Amary F, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) Distinct H3F3A and H3F3B driver variants define chondroblastoma and giant cell tumour of bone. Nat Genet45:1479-82. doi: 10.1038/ng.2814 

For tiden bruker vi en del av disse resultatene i et prosjekt der vi prøver å forstå hvorfor noen sarkomtyper og hvilke enkeltsvulster responderer på immunterapi og andre ikke, i et prosjekt finansiert av Norges Forskningsråd. Det viste seg i en amerikansk klinisk utprøving der både bløtvevs- og bensarkomer ble behandlet med immunsjekkpunkthemmeren pembrolizumab (SARC028) at bare en osteosarkompasient fikk respons, mens en rekke pasienter med bestemte typer bløtvessarkom responderte.

Publications 2020

Akdemir KC, Le VT, Chandran S, Li Y, Verhaak RG, Beroukhim R, Campbell PJ, Chin L, Dixon JR, Futreal PA; PCAWG Structural Variation Working Group; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 52:294-305. doi: 10.1038/s41588-019-0564-y
Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V; PCAWG Mutational Signatures Working Group; Getz G, Rozen SG, Stratton MR; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) The repertoire of mutational signatures in human cancer. Nature 578:94-101. doi: 10.1038/s41586-020-1943-3

Bailey MH, Meyerson WU, Dursi LJ,  ….., Gerstein MB, Ding L & PCAWG Consortium [including Bjerkehagen B, Myklebost O, Zaikova O] (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples Nature Communications volume 11, Article number: 4748 DOI: 10.1038/s41467-020-18151-y  

Bhandari V, Li CH, Bristow RG, Boutros PC; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun. 11:737. doi: 10.1038/s41467-019-14052-x

Carlevaro-Fita J, Lanzós A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS; PCAWG Drivers and Functional Interpretation Group; Johnson R; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,Myklebost O] (2020) Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol. 3:56. doi: 10.1038/s42003-019-0741-7

Cmero M, Yuan K, Ong CS, Schröder J; PCAWG Evolution and Heterogeneity Working Group; Corcoran NM, Papenfuss T, Hovens CM, Markowetz F, Macintyre G; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Inferring structural variant cancer cell fraction. Nat Commun. 11:730. doi: 10.1038/s41467-020-14351-8

Cortés-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS; PCAWG Structural Variation Working Group; Park PJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet. 52:331-341. doi: 10.1038/s41588-019-0576-7

Dörnen J, Myklebost O, Dittmar (2020) Cell Fusion of Mesenchymal Stem/Stromal Cells and Breast Cancer Cells leads to the Formation of Hybrid Cells exhibiting diverse and individual (stem cell) Characteristics. International Journal of Molecular Sciences

Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution & Heterogeneity Working Group; Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) The evolutionary history of 2,658 cancers. Nature 578:122-128. doi: 10.1038/s41586-019-1907-7

Jiao W, Atwal G, Polak P, Karlic R, Cuppen E; PCAWG Tumor Subtypes and Clinical Translation Working Group; Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N, Getz G, Morris QD, Stein LD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun.11:728. doi: 10.1038/s41467-019-13825-8

Li CH, Prokopec SD, Sun R, Yousif F, Schmitz N, PCAWG Tumour Subtypes and Clinical Translation, Boutros PC, PCAWG Consortium (Including Bjerkehagen B, Myklebost O, Zaikova O) (2020) Sex differences in oncogenic mutational processes. Nature Communications 11:4330 DOI: 10.1038/s41467-020-17359-2

Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, Imielinski M; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Campbell PJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Patterns of somatic structural variation in human cancer genomes. Nature 578:112-121. doi: 10.1038/s41586-019-1913-9

Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC; PCAWG Drivers and Functional Interpretation Working Group; Reimand J; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Integrative pathway enrichment analysis of multivariate omics data. Nat Commun. 11:735. doi: 10.1038/s41467-019-13983-9

PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarström Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H; PCAWG Transcriptome Working Group; Brazma A, Brooks AN, Göke J, Rätsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Genomic basis for RNA alterations in cancer. Nature 578:129-136. doi: 10.1038/s41586-020-1970-0

Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Izarzugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A; PCAWG Drivers and Functional Interpretation Working Group; Reimand J, Stuart JM, Raphael BJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun. 11:729. doi: 10.1038/s41467-020-14367-0

Rheinbay E, Nielsen MM, Abascal F, … ; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G; PCAWG Consortium  [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature 578:102-111. doi: 10.1038/s41586-020-1965-x

Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, …, PCAWG Structural Variation Working Group; Campbell PJ, Tubio JMC; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,Myklebost O] (2020) Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 52:306-319. doi: 10.1038/s41588-019-0562-0

Rubanova Y, Shi R, Harrigan CF, Li R, Wintersinger J, Sahin N, Deshwar AG; PCAWG Evolution and Heterogeneity Working Group; Morris QD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,Myklebost O] (2020) Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun. 11:731. doi: 10.1038/s41467-020-14352-7

Serguienko A, Braadland P, Meza-Zepeda LA, Bjerkehagen B, Myklebost O (2020) Accurate 3-gene-signature for early diagnosis of liposarcoma progression. Clinical Sarcoma Research 10:4 DOI: 10.1186/s13569-020-0126-1.

Shuai S; PCAWG Drivers and Functional Interpretation Working Group; Gallinger S, Stein LD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun. 11:734. doi: 10.1038/s41467-019-13929-1 

Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cortés-Ciriano I, Xi R, Kabbe R, Park PJ, Eils R, Schlesner M; PCAWG-Structural Variation Working Group; Brors B, Rippe K, Jones DTW, Feuerbach L; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun. 11:733. doi: 10.1038/s41467-019-13824-9

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium [Incl Bjerkehagen B, Myklebost O, Zaikova O] (2020) Pan-cancer analysis of whole genomes. Nature 578:82–93 doi:10.1038/s41586-020-1969-6 

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020) Mutational Dynamics and Immune Evasion in Diffuse Large B-cell Lymphoma: A Call for Relapse Sampling Blood Adv 12;4(9):1859-1866. doi: 10.1182/bloodadvances.2019001325. 

Yakneen S, Waszak SM; PCAWG Technical Working Group; Gertz M, Korbel JO; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol. 38:288-292. doi: 10.1038/s41587-019-0360-3

Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 52:342-352. doi: 10.1038/s41588-019-0557-x

Zhang Y, Chen F, Fonseca NA, He Y, Fujita M, Nakagawa H, Zhang Z, Brazma A; PCAWG Transcriptome Working Group; PCAWG Structural Variation Working Group; Creighton CJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O] (2020) High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun. 11:736. doi: 10.1038/s41467-019-13885-w